{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T03:38:02Z","timestamp":1790048282664,"version":"4.0.1"},"reference-count":83,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2024,7,23]],"date-time":"2024-07-23T00:00:00Z","timestamp":1721692800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,7,23]],"date-time":"2024-07-23T00:00:00Z","timestamp":1721692800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/100000968","name":"American Heart Association","doi-asserted-by":"publisher","award":["23POST1020812"],"award-info":[{"award-number":["23POST1020812"]}],"id":[{"id":"10.13039\/100000968","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000968","name":"American Heart Association","doi-asserted-by":"publisher","award":["SFRN grant 869015"],"award-info":[{"award-number":["SFRN grant 869015"]}],"id":[{"id":"10.13039\/100000968","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["NIH K99 HL163443-01A1"],"award-info":[{"award-number":["NIH K99 HL163443-01A1"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R01 HL158641, R01 HL161002"],"award-info":[{"award-number":["R01 HL158641, R01 HL161002"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Cardiol Rep"],"published-print":{"date-parts":[[2024,9]]},"DOI":"10.1007\/s11886-024-02099-2","type":"journal-article","created":{"date-parts":[[2024,7,23]],"date-time":"2024-07-23T12:19:01Z","timestamp":1721737141000},"page":"953-971","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Cardiovascular Toxicity in Cancer Therapy: Protecting the Heart while Combating Cancer"],"prefix":"10.1007","volume":"26","author":[{"given":"Amit","family":"Manhas","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dipti","family":"Tripathi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dilip","family":"Thomas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nazish","family":"Sayed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,7,23]]},"reference":[{"issue":"5","key":"2099_CR1","doi-asserted-by":"publisher","first-page":"409","DOI":"10.3322\/caac.21731","volume":"72","author":"KD Miller","year":"2022","unstructured":"Miller KD, Nogueira L, Devasia T, Mariotto AB, Yabroff KR, Jemal A, et al. Cancer treatment and survivorship statistics, 2022. CA Cancer J Clin. 2022;72(5):409\u201336. https:\/\/doi.org\/10.3322\/caac.21731.","journal-title":"CA Cancer J Clin"},{"issue":"1","key":"2099_CR2","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3322\/caac.21708","volume":"72","author":"RL Siegel","year":"2022","unstructured":"Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer statistics, 2022. CA Cancer J Clin. 2022;72(1):7\u201333. https:\/\/doi.org\/10.3322\/caac.21708.","journal-title":"CA Cancer J Clin"},{"issue":"1","key":"2099_CR3","doi-asserted-by":"publisher","first-page":"17","DOI":"10.3322\/caac.21763","volume":"73","author":"RL Siegel","year":"2023","unstructured":"Siegel RL, Miller KD, Wagle NS, Jemal A. Cancer statistics, 2023. CA Cancer J Clin. 2023;73(1):17\u201348. https:\/\/doi.org\/10.3322\/caac.21763.","journal-title":"CA Cancer J Clin"},{"issue":"1","key":"2099_CR4","doi-asserted-by":"publisher","first-page":"12","DOI":"10.3322\/caac.21820","volume":"74","author":"RL Siegel","year":"2024","unstructured":"Siegel RL, Giaquinto AN, Jemal A. Cancer statistics, 2024. CA Cancer J Clin. 2024;74(1):12\u201349. https:\/\/doi.org\/10.3322\/caac.21820.","journal-title":"CA Cancer J Clin"},{"issue":"49","key":"2099_CR5","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1093\/jncimonographs\/lgu024","volume":"2014","author":"AB Mariotto","year":"2014","unstructured":"Mariotto AB, Noone AM, Howlader N, Cho H, Keel GE, Garshell J, et al. Cancer survival: an overview of measures, uses, and interpretation. J Natl Cancer Inst Monogr. 2014;2014(49):145\u201386. https:\/\/doi.org\/10.1093\/jncimonographs\/lgu024.","journal-title":"J Natl Cancer Inst Monogr"},{"issue":"5","key":"2099_CR6","doi-asserted-by":"publisher","first-page":"363","DOI":"10.3322\/caac.21565","volume":"69","author":"KD Miller","year":"2019","unstructured":"Miller KD, Nogueira L, Mariotto AB, Rowland JH, Yabroff KR, Alfano CM, et al. Cancer treatment and survivorship statistics, 2019. CA Cancer J Clin. 2019;69(5):363\u201385. https:\/\/doi.org\/10.3322\/caac.21565.","journal-title":"CA Cancer J Clin"},{"issue":"6","key":"2099_CR7","doi-asserted-by":"publisher","first-page":"1053","DOI":"10.1016\/j.mcna.2017.06.003","volume":"101","author":"N Gegechkori","year":"2017","unstructured":"Gegechkori N, Haines L, Lin JJ. Long-Term and Latent Side Effects of Specific Cancer Types. Med Clin North Am. 2017;101(6):1053\u201373. https:\/\/doi.org\/10.1016\/j.mcna.2017.06.003.","journal-title":"Med Clin North Am"},{"issue":"10","key":"2099_CR8","doi-asserted-by":"publisher","first-page":"1122","DOI":"10.1200\/JCO.2015.64.0409","volume":"34","author":"SH Armenian","year":"2016","unstructured":"Armenian SH, Xu L, Ky B, Sun C, Farol LT, Pal SK, et al. Cardiovascular Disease Among Survivors of Adult-Onset Cancer: A Community-Based Retrospective Cohort Study. J Clin Oncol. 2016;34(10):1122\u201330. https:\/\/doi.org\/10.1200\/JCO.2015.64.0409.","journal-title":"J Clin Oncol"},{"issue":"13","key":"2099_CR9","doi-asserted-by":"publisher","first-page":"1090","DOI":"10.1200\/JCO.18.01764","volume":"37","author":"JE Bates","year":"2019","unstructured":"Bates JE, Howell RM, Liu Q, Yasui Y, Mulrooney DA, Dhakal S, et al. Therapy-Related Cardiac Risk in Childhood Cancer Survivors: An Analysis of the Childhood Cancer Survivor Study. J Clin Oncol. 2019;37(13):1090\u2013101. https:\/\/doi.org\/10.1200\/JCO.18.01764.","journal-title":"J Clin Oncol"},{"issue":"10203","key":"2099_CR10","doi-asserted-by":"publisher","first-page":"1041","DOI":"10.1016\/S0140-6736(19)31674-5","volume":"394","author":"H Strongman","year":"2019","unstructured":"Strongman H, Gadd S, Matthews A, Mansfield KE, Stanway S, Lyon AR, et al. Medium and long-term risks of specific cardiovascular diseases in survivors of 20 adult cancers: a population-based cohort study using multiple linked UK electronic health records databases. Lancet. 2019;394(10203):1041\u201354. https:\/\/doi.org\/10.1016\/S0140-6736(19)31674-5.","journal-title":"Lancet"},{"issue":"12","key":"2099_CR11","doi-asserted-by":"publisher","first-page":"1218","DOI":"10.1200\/JCO.2013.51.1055","volume":"32","author":"GT Armstrong","year":"2014","unstructured":"Armstrong GT, Kawashima T, Leisenring W, Stratton K, Stovall M, Hudson MM, et al. Aging and risk of severe, disabling, life-threatening, and fatal events in the childhood cancer survivor study. J Clin Oncol. 2014;32(12):1218\u201327. https:\/\/doi.org\/10.1200\/JCO.2013.51.1055.","journal-title":"J Clin Oncol"},{"issue":"22","key":"2099_CR12","doi-asserted-by":"publisher","first-page":"2371","DOI":"10.1001\/jama.2013.6296","volume":"309","author":"MM Hudson","year":"2013","unstructured":"Hudson MM, Ness KK, Gurney JG, Mulrooney DA, Chemaitilly W, Krull KR, et al. Clinical ascertainment of health outcomes among adults treated for childhood cancer. JAMA. 2013;309(22):2371\u201381. https:\/\/doi.org\/10.1001\/jama.2013.6296.","journal-title":"JAMA"},{"issue":"1","key":"2099_CR13","doi-asserted-by":"publisher","first-page":"8","DOI":"10.4021\/jocmr2009.02.1225","volume":"1","author":"DK Shakir","year":"2009","unstructured":"Shakir DK, Rasul KI. Chemotherapy induced cardiomyopathy: pathogenesis, monitoring and management. J Clin Med Res. 2009;1(1):8\u201312. https:\/\/doi.org\/10.4021\/jocmr2009.02.1225.","journal-title":"J Clin Med Res"},{"issue":"23","key":"2099_CR14","doi-asserted-by":"publisher","first-page":"2456","DOI":"10.1056\/NEJM200506093522321","volume":"352","author":"ER Hayek","year":"2005","unstructured":"Hayek ER, Speakman E, Rehmus E. Acute doxorubicin cardiotoxicity. N Engl J Med. 2005;352(23):2456\u20137. https:\/\/doi.org\/10.1056\/NEJM200506093522321.","journal-title":"N Engl J Med"},{"issue":"2","key":"2099_CR15","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1159\/000265166","volume":"115","author":"K Chatterjee","year":"2010","unstructured":"Chatterjee K, Zhang J, Honbo N, Karliner JS. Doxorubicin cardiomyopathy. Cardiology. 2010;115(2):155\u201362. https:\/\/doi.org\/10.1159\/000265166.","journal-title":"Cardiology"},{"key":"2099_CR16","doi-asserted-by":"publisher","first-page":"44735","DOI":"10.1038\/srep44735","volume":"7","author":"L Zhao","year":"2017","unstructured":"Zhao L, Zhang B. Doxorubicin induces cardiotoxicity through upregulation of death receptors mediated apoptosis in cardiomyocytes. Sci Rep. 2017;7:44735. https:\/\/doi.org\/10.1038\/srep44735.","journal-title":"Sci Rep"},{"issue":"1","key":"2099_CR17","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1021\/acs.chemrestox.9b00387","volume":"33","author":"SD Lamore","year":"2020","unstructured":"Lamore SD, Kohnken RA, Peters MF, Kolaja KL. Cardiovascular Toxicity Induced by Kinase Inhibitors: Mechanisms and Preclinical Approaches. Chem Res Toxicol. 2020;33(1):125\u201336. https:\/\/doi.org\/10.1021\/acs.chemrestox.9b00387.","journal-title":"Chem Res Toxicol"},{"issue":"5","key":"2099_CR18","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1016\/j.jaccao.2022.09.003","volume":"4","author":"L Kondapalli","year":"2022","unstructured":"Kondapalli L, Hsia J, Miller R, Flaig TW, Bonaca MP. Burden of Cardiovascular Disease in Immune Checkpoint Inhibitor-Treated Patients: Reconciling Adjudicated and Coded Outcomes. JACC CardioOncol. 2022;4(5):649\u201356. https:\/\/doi.org\/10.1016\/j.jaccao.2022.09.003.","journal-title":"JACC CardioOncol"},{"issue":"4 Suppl 10","key":"2099_CR19","first-page":"15","volume":"25","author":"EH Herman","year":"1998","unstructured":"Herman EH, Ferrans VJ. Preclinical animal models of cardiac protection from anthracycline-induced cardiotoxicity. Semin Oncol. 1998;25(4 Suppl 10):15\u201321.","journal-title":"Semin Oncol"},{"key":"2099_CR20","doi-asserted-by":"publisher","unstructured":"Sayed N, Liu C, Ameen M, Himmati F, Zhang JZ, Khanamiri S, et al. Clinical trial in a dish using iPSCs shows lovastatin improves endothelial dysfunction and cellular cross-talk in LMNA cardiomyopathy. Sci Transl Med. 2020;12(554). https:\/\/doi.org\/10.1126\/scitranslmed.aax9276.","DOI":"10.1126\/scitranslmed.aax9276"},{"key":"2099_CR21","doi-asserted-by":"publisher","unstructured":"Liu C, Oikonomopoulos A, Sayed N, Wu JC. Modeling human diseases with induced pluripotent stem cells: from 2D to 3D and beyond. Development. 2018;145(5). https:\/\/doi.org\/10.1242\/dev.156166.","DOI":"10.1242\/dev.156166"},{"issue":"6","key":"2099_CR22","doi-asserted-by":"publisher","first-page":"1232","DOI":"10.1016\/j.stemcr.2019.04.017","volume":"12","author":"A Bozzi","year":"2019","unstructured":"Bozzi A, Sayed N, Matsa E, Sass G, Neofytou E, Clemons KV, et al. Using Human Induced Pluripotent Stem Cell-Derived Cardiomyocytes as a Model to Study Trypanosoma cruzi Infection. Stem Cell Rep. 2019;12(6):1232\u201341. https:\/\/doi.org\/10.1016\/j.stemcr.2019.04.017.","journal-title":"Stem Cell Rep"},{"issue":"7","key":"2099_CR23","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1139\/cjpp-2015-0459","volume":"94","author":"M Csobonyeiova","year":"2016","unstructured":"Csobonyeiova M, Polak S, Danisovic L. Toxicity testing and drug screening using iPSC-derived hepatocytes, cardiomyocytes, and neural cells. Can J Physiol Pharmacol. 2016;94(7):687\u201394. https:\/\/doi.org\/10.1139\/cjpp-2015-0459.","journal-title":"Can J Physiol Pharmacol"},{"issue":"14","key":"2099_CR24","doi-asserted-by":"publisher","first-page":"1208","DOI":"10.1161\/CIRCULATIONAHA.118.035906","volume":"141","author":"L Tian","year":"2020","unstructured":"Tian L, Oikonomopoulos A, Liu C, Kitani T, Shrestha R, Chen CL, et al. Molecular Signatures of Beneficial Class Effects of Statins on Human Induced Pluripotent Stem Cell-Derived Cardiomyocytes. Circulation. 2020;141(14):1208\u201310. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.118.035906.","journal-title":"Circulation"},{"issue":"3","key":"2099_CR25","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1016\/j.stem.2016.07.006","volume":"19","author":"E Matsa","year":"2016","unstructured":"Matsa E, Burridge PW, Yu KH, Ahrens JH, Termglinchan V, Wu H, et al. Transcriptome Profiling of Patient-Specific Human iPSC-Cardiomyocytes Predicts Individual Drug Safety and Efficacy Responses In Vitro. Cell Stem Cell. 2016;19(3):311\u201325. https:\/\/doi.org\/10.1016\/j.stem.2016.07.006.","journal-title":"Cell Stem Cell"},{"issue":"17","key":"2099_CR26","doi-asserted-by":"publisher","first-page":"1367","DOI":"10.1161\/CIRCULATIONAHA.121.054317","volume":"145","author":"K Sallam","year":"2022","unstructured":"Sallam K, Thomas D, Gaddam S, Lopez N, Beck A, Beach L, et al. Modeling Effects of Immunosuppressive Drugs on Human Hearts Using Induced Pluripotent Stem Cell-Derived Cardiac Organoids and Single-Cell RNA Sequencing. Circulation. 2022;145(17):1367\u20139. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.121.054317.","journal-title":"Circulation"},{"key":"2099_CR27","doi-asserted-by":"publisher","first-page":"607364","DOI":"10.3389\/fphar.2021.607364","volume":"12","author":"D Thomas","year":"2021","unstructured":"Thomas D, Shenoy S, Sayed N. Building Multi-Dimensional Induced Pluripotent Stem Cells-Based Model Platforms to Assess Cardiotoxicity in Cancer Therapies. Front Pharmacol. 2021;12:607364. https:\/\/doi.org\/10.3389\/fphar.2021.607364.","journal-title":"Front Pharmacol"},{"issue":"21","key":"2099_CR28","doi-asserted-by":"publisher","first-page":"2451","DOI":"10.1161\/CIRCULATIONAHA.118.037357","volume":"139","author":"T Kitani","year":"2019","unstructured":"Kitani T, Ong SG, Lam CK, Rhee JW, Zhang JZ, Oikonomopoulos A, et al. Human-Induced Pluripotent Stem Cell Model of Trastuzumab-Induced Cardiac Dysfunction in Patients With Breast Cancer. Circulation. 2019;139(21):2451\u201365. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.118.037357.","journal-title":"Circulation"},{"issue":"5","key":"2099_CR29","doi-asserted-by":"publisher","first-page":"949","DOI":"10.1093\/cvr\/cvz024","volume":"115","author":"N Sayed","year":"2019","unstructured":"Sayed N, Ameen M, Wu JC. Personalized medicine in cardio-oncology: the role of induced pluripotent stem cell. Cardiovasc Res. 2019;115(5):949\u201359. https:\/\/doi.org\/10.1093\/cvr\/cvz024.","journal-title":"Cardiovasc Res"},{"key":"2099_CR30","doi-asserted-by":"publisher","unstructured":"Sharma A, Burridge PW, McKeithan WL, Serrano R, Shukla P, Sayed N, et al. High-throughput screening of tyrosine kinase inhibitor cardiotoxicity with human induced pluripotent stem cells. Sci Transl Med. 2017;9(377). https:\/\/doi.org\/10.1126\/scitranslmed.aaf2584.","DOI":"10.1126\/scitranslmed.aaf2584"},{"issue":"22","key":"2099_CR31","doi-asserted-by":"publisher","first-page":"1764","DOI":"10.1093\/eurheartj\/ehx811","volume":"40","author":"JP Stack","year":"2019","unstructured":"Stack JP, Moslehi J, Sayed N, Wu JC. Cancer therapy-induced cardiomyopathy: can human induced pluripotent stem cell modelling help prevent it? Eur Heart J. 2019;40(22):1764\u201370. https:\/\/doi.org\/10.1093\/eurheartj\/ehx811.","journal-title":"Eur Heart J"},{"issue":"18","key":"2099_CR32","doi-asserted-by":"publisher","first-page":"2161","DOI":"10.1016\/j.jacc.2016.01.083","volume":"67","author":"N Sayed","year":"2016","unstructured":"Sayed N, Liu C, Wu JC. Translation of Human-Induced Pluripotent Stem Cells: From Clinical Trial in a Dish to Precision Medicine. J Am Coll Cardiol. 2016;67(18):2161\u201376. https:\/\/doi.org\/10.1016\/j.jacc.2016.01.083.","journal-title":"J Am Coll Cardiol"},{"issue":"Suppl 1","key":"2099_CR33","doi-asserted-by":"publisher","first-page":"71","DOI":"10.4137\/BMI.S20050","volume":"10","author":"I Batalov","year":"2015","unstructured":"Batalov I, Feinberg AW. Differentiation of Cardiomyocytes from Human Pluripotent Stem Cells Using Monolayer Culture. Biomark Insights. 2015;10(Suppl 1):71\u20136. https:\/\/doi.org\/10.4137\/BMI.S20050.","journal-title":"Biomark Insights"},{"issue":"7","key":"2099_CR34","doi-asserted-by":"publisher","first-page":"1188","DOI":"10.1016\/j.stem.2021.05.002","volume":"28","author":"J Nguyen","year":"2021","unstructured":"Nguyen J, Lin YY, Gerecht S. The next generation of endothelial differentiation: Tissue-specific ECs. Cell Stem Cell. 2021;28(7):1188\u2013204. https:\/\/doi.org\/10.1016\/j.stem.2021.05.002.","journal-title":"Cell Stem Cell"},{"issue":"2","key":"2099_CR35","doi-asserted-by":"publisher","first-page":"102292","DOI":"10.1016\/j.xpro.2023.102292","volume":"4","author":"TS Park","year":"2023","unstructured":"Park TS, Hirday R, Ali A, Megersa R, Villasmil R, Nguyen E, et al. Protocol to generate endothelial cells, pericytes, and fibroblasts in one differentiation round from human-induced pluripotent stem cells. STAR Protoc. 2023;4(2):102292. https:\/\/doi.org\/10.1016\/j.xpro.2023.102292.","journal-title":"STAR Protoc"},{"key":"2099_CR36","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/j.reth.2022.12.001","volume":"22","author":"Q Liu","year":"2023","unstructured":"Liu Q, Liu Z, Gu H, Ge Y, Wu X, Zuo F, et al. Comparative study of differentiating human pluripotent stem cells into vascular smooth muscle cells in hydrogel-based culture methods. Regen Ther. 2023;22:39\u201349. https:\/\/doi.org\/10.1016\/j.reth.2022.12.001.","journal-title":"Regen Ther"},{"issue":"27","key":"2099_CR37","doi-asserted-by":"publisher","first-page":"E1848","DOI":"10.1073\/pnas.1200250109","volume":"109","author":"X Lian","year":"2012","unstructured":"Lian X, Hsiao C, Wilson G, Zhu K, Hazeltine LB, Azarin SM, et al. Robust cardiomyocyte differentiation from human pluripotent stem cells via temporal modulation of canonical Wnt signaling. Proc Natl Acad Sci U S A. 2012;109(27):E1848\u201357. https:\/\/doi.org\/10.1073\/pnas.1200250109.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"9","key":"2099_CR38","doi-asserted-by":"publisher","first-page":"1119","DOI":"10.1038\/cr.2013.102","volume":"23","author":"N Cao","year":"2013","unstructured":"Cao N, Liang H, Huang J, Wang J, Chen Y, Chen Z, et al. Highly efficient induction and long-term maintenance of multipotent cardiovascular progenitors from human pluripotent stem cells under defined conditions. Cell Res. 2013;23(9):1119\u201332. https:\/\/doi.org\/10.1038\/cr.2013.102.","journal-title":"Cell Res"},{"issue":"8","key":"2099_CR39","doi-asserted-by":"publisher","first-page":"855","DOI":"10.1038\/nmeth.2999","volume":"11","author":"PW Burridge","year":"2014","unstructured":"Burridge PW, Matsa E, Shukla P, Lin ZC, Churko JM, Ebert AD, et al. Chemically defined generation of human cardiomyocytes. Nat Methods. 2014;11(8):855\u201360. https:\/\/doi.org\/10.1038\/nmeth.2999.","journal-title":"Nat Methods"},{"issue":"1","key":"2099_CR40","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1016\/j.stem.2020.06.001","volume":"27","author":"JW Buikema","year":"2020","unstructured":"Buikema JW, Lee S, Goodyer WR, Maas RG, Chirikian O, Li G, et al. Wnt Activation and Reduced Cell-Cell Contact Synergistically Induce Massive Expansion of Functional Human iPSC-Derived Cardiomyocytes. Cell Stem Cell. 2020;27(1):50-63e5. https:\/\/doi.org\/10.1016\/j.stem.2020.06.001.","journal-title":"Cell Stem Cell."},{"issue":"1","key":"2099_CR41","doi-asserted-by":"publisher","first-page":"e64","DOI":"10.1002\/cphg.64","volume":"98","author":"M Gu","year":"2018","unstructured":"Gu M. Efficient Differentiation of Human Pluripotent Stem Cells to Endothelial Cells. Curr Protoc Hum Genet. 2018;98(1):e64. https:\/\/doi.org\/10.1002\/cphg.64.","journal-title":"Curr Protoc Hum Genet"},{"issue":"1","key":"2099_CR42","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1186\/s13287-022-02924-x","volume":"13","author":"S Hamad","year":"2022","unstructured":"Hamad S, Derichsweiler D, Gaspar JA, Brockmeier K, Hescheler J, Sachinidis A, et al. High-efficient serum-free differentiation of endothelial cells from human iPS cells. Stem Cell Res Ther. 2022;13(1):251. https:\/\/doi.org\/10.1186\/s13287-022-02924-x.","journal-title":"Stem Cell Res Ther"},{"key":"2099_CR43","doi-asserted-by":"publisher","unstructured":"Gao X, Gao M, Gorecka J, Langford J, Liu J, Luo J, et al. Human-Induced Pluripotent Stem-Cell-Derived Smooth Muscle Cells Increase Angiogenesis to Treat Hindlimb Ischemia. Cells. 2021;10(4). https:\/\/doi.org\/10.3390\/cells10040792.","DOI":"10.3390\/cells10040792"},{"issue":"8","key":"2099_CR44","doi-asserted-by":"publisher","first-page":"994","DOI":"10.1038\/ncb3205","volume":"17","author":"C Patsch","year":"2015","unstructured":"Patsch C, Challet-Meylan L, Thoma EC, Urich E, Heckel T, O\u2019Sullivan JF, et al. Generation of vascular endothelial and smooth muscle cells from human pluripotent stem cells. Nat Cell Biol. 2015;17(8):994\u20131003. https:\/\/doi.org\/10.1038\/ncb3205.","journal-title":"Nat Cell Biol"},{"issue":"1","key":"2099_CR45","doi-asserted-by":"publisher","first-page":"2238","DOI":"10.1038\/s41467-019-09831-5","volume":"10","author":"J Zhang","year":"2019","unstructured":"Zhang J, Tao R, Campbell KF, Carvalho JL, Ruiz EC, Kim GC, et al. Functional cardiac fibroblasts derived from human pluripotent stem cells via second heart field progenitors. Nat Commun. 2019;10(1):2238. https:\/\/doi.org\/10.1038\/s41467-019-09831-5.","journal-title":"Nat Commun"},{"issue":"5","key":"2099_CR46","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1161\/CIRCRESAHA.119.315491","volume":"125","author":"H Zhang","year":"2019","unstructured":"Zhang H, Tian L, Shen M, Tu C, Wu H, Gu M, et al. Generation of Quiescent Cardiac Fibroblasts From Human Induced Pluripotent Stem Cells for In Vitro Modeling of Cardiac Fibrosis. Circ Res. 2019;125(5):552\u201366. https:\/\/doi.org\/10.1161\/CIRCRESAHA.119.315491.","journal-title":"Circ Res"},{"issue":"1","key":"2099_CR47","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1186\/s12872-022-02543-7","volume":"22","author":"D Thomas","year":"2022","unstructured":"Thomas D, de Jesus Perez VA, Sayed N. An evidence appraisal of heart organoids in a dish and commensurability to human heart development in vivo. BMC Cardiovasc Disord. 2022;22(1):122. https:\/\/doi.org\/10.1186\/s12872-022-02543-7.","journal-title":"BMC Cardiovasc Disord"},{"issue":"12","key":"2099_CR48","doi-asserted-by":"publisher","first-page":"1780","DOI":"10.1161\/CIRCRESAHA.122.320305","volume":"130","author":"D Thomas","year":"2022","unstructured":"Thomas D, Choi S, Alamana C, Parker KK, Wu JC. Cellular and Engineered Organoids for Cardiovascular Models. Circ Res. 2022;130(12):1780\u2013802. https:\/\/doi.org\/10.1161\/CIRCRESAHA.122.320305.","journal-title":"Circ Res"},{"issue":"1","key":"2099_CR49","doi-asserted-by":"publisher","first-page":"2564","DOI":"10.1038\/s41467-024-46928-y","volume":"15","author":"S Min","year":"2024","unstructured":"Min S, Kim S, Sim WS, Choi YS, Joo H, Park JH, et al. Versatile human cardiac tissues engineered with perfusable heart extracellular microenvironment for biomedical applications. Nat Commun. 2024;15(1):2564. https:\/\/doi.org\/10.1038\/s41467-024-46928-y.","journal-title":"Nat Commun"},{"key":"2099_CR50","doi-asserted-by":"publisher","unstructured":"Li J, Hua Y, Miyagawa S, Zhang J, Li L, Liu L, et al. hiPSC-Derived Cardiac Tissue for Disease Modeling and Drug Disc. Int J Mol Sci. 2020;21(23). https:\/\/doi.org\/10.3390\/ijms21238893.","DOI":"10.3390\/ijms21238893"},{"key":"2099_CR51","doi-asserted-by":"publisher","unstructured":"Varzideh F, Mone P, Santulli G. Bioengineering Strategies to Create 3D Cardiac Constructs from Human Induced Pluripotent Stem Cells. Bioengineering (Basel). 2022;9(4). https:\/\/doi.org\/10.3390\/bioengineering9040168.","DOI":"10.3390\/bioengineering9040168"},{"key":"2099_CR52","doi-asserted-by":"publisher","unstructured":"Arai K, Kitsuka T, Nakayama K. Scaffold-based and scaffold-free cardiac constructs for drug testing. Biofabrication. 2021;13(4). https:\/\/doi.org\/10.1088\/1758-5090\/ac1257","DOI":"10.1088\/1758-5090\/ac1257"},{"issue":"14","key":"2099_CR53","doi-asserted-by":"publisher","first-page":"1014","DOI":"10.1093\/eurheartj\/ehx089","volume":"38","author":"N Sayed","year":"2017","unstructured":"Sayed N, Wu JC. Towards Cardio-Precision medicine. Eur Heart J. 2017;38(14):1014\u20136. https:\/\/doi.org\/10.1093\/eurheartj\/ehx089.","journal-title":"Eur Heart J"},{"issue":"29","key":"2099_CR54","doi-asserted-by":"publisher","first-page":"e26629","DOI":"10.1097\/MD.0000000000026629","volume":"100","author":"Y Lu","year":"2021","unstructured":"Lu Y, Hua J, Yan F, Jiang C, Piao Y, Ye Z, et al. Combined radiotherapy and chemotherapy versus radiotherapy alone in elderly patients with nasopharyngeal carcinoma: A SEER population-based study. Medicine (Baltimore). 2021;100(29):e26629. https:\/\/doi.org\/10.1097\/MD.0000000000026629.","journal-title":"Medicine (Baltimore)"},{"issue":"20","key":"2099_CR55","doi-asserted-by":"publisher","first-page":"2552","DOI":"10.1016\/j.jacc.2017.09.1095","volume":"70","author":"HM Chang","year":"2017","unstructured":"Chang HM, Okwuosa TM, Scarabelli T, Moudgil R, Yeh ETH. Cardiovascular Complications of Cancer Therapy: Best Practices in Diagnosis, Prevention, and Management: Part 2. J Am Coll Cardiol. 2017;70(20):2552\u201365. https:\/\/doi.org\/10.1016\/j.jacc.2017.09.1095.","journal-title":"J Am Coll Cardiol"},{"issue":"7","key":"2099_CR56","doi-asserted-by":"publisher","first-page":"5","DOI":"10.3390\/cancers13071712","volume":"13","author":"AA Diaz-Gavela","year":"2021","unstructured":"Diaz-Gavela AA, Figueiras-Graillet L, Luis AM, Salas Segura J, Ciervide R, Del Cerro Penalver E, et al. Breast Radiotherapy-Related Cardiotoxicity. When, How, Why Risk Prevention and Control Strategies. Cancers (Basel). 2021;13(7):5\u20135. https:\/\/doi.org\/10.3390\/cancers13071712.","journal-title":"Cancers (Basel)"},{"issue":"41","key":"2099_CR57","doi-asserted-by":"publisher","first-page":"e5051","DOI":"10.1097\/MD.0000000000005051","volume":"95","author":"X Ming","year":"2016","unstructured":"Ming X, Feng Y, Yang C, Wang W, Wang P, Deng J. Radiation-induced heart disease in lung cancer radiotherapy: A dosimetric update. Medicine (Baltimore). 2016;95(41):e5051. https:\/\/doi.org\/10.1097\/MD.0000000000005051.","journal-title":"Medicine (Baltimore)"},{"issue":"6","key":"2099_CR58","doi-asserted-by":"publisher","first-page":"C1320","DOI":"10.1152\/ajpcell.00466.2022","volume":"324","author":"J Yi","year":"2023","unstructured":"Yi J, Yue L, Zhang Y, Tao N, Duan H, Lv L, et al. PTPMT1 protects cardiomyocytes from necroptosis induced by gamma-ray irradiation through alleviating mitochondria injury. Am J Physiol Cell Physiol. 2023;324(6):C1320\u201331. https:\/\/doi.org\/10.1152\/ajpcell.00466.2022.","journal-title":"Am J Physiol Cell Physiol"},{"issue":"45","key":"2099_CR59","doi-asserted-by":"publisher","first-page":"eabn6579","DOI":"10.1126\/sciadv.abn6579","volume":"8","author":"JKE Spetz","year":"2022","unstructured":"Spetz JKE, Florido MHC, Fraser CS, Qin X, Choiniere J, Yu SJ, et al. Heightened apoptotic priming of vascular cells across tissues and life span predisposes them to cancer therapy-induced toxicities. Sci Adv. 2022;8(45):eabn6579. https:\/\/doi.org\/10.1126\/sciadv.abn6579.","journal-title":"Sci Adv"},{"issue":"7","key":"2099_CR60","doi-asserted-by":"publisher","first-page":"4627","DOI":"10.1111\/jcmm.14346","volume":"23","author":"N Cui","year":"2019","unstructured":"Cui N, Wu F, Lu WJ, Bai R, Ke B, Liu T, et al. Doxorubicin-induced cardiotoxicity is maturation dependent due to the shift from topoisomerase IIalpha to IIbeta in human stem cell derived cardiomyocytes. J Cell Mol Med. 2019;23(7):4627\u201339. https:\/\/doi.org\/10.1111\/jcmm.14346.","journal-title":"J Cell Mol Med"},{"issue":"6","key":"2099_CR61","doi-asserted-by":"publisher","first-page":"2113","DOI":"10.1007\/s00204-020-02711-8","volume":"94","author":"ST Karhu","year":"2020","unstructured":"Karhu ST, Kinnunen SM, Tolli M, Valimaki MJ, Szabo Z, Talman V, et al. GATA4-targeted compound exhibits cardioprotective actions against doxorubicin-induced toxicity in vitro and in vivo: establishment of a chronic cardiotoxicity model using human iPSC-derived cardiomyocytes. Arch Toxicol. 2020;94(6):2113\u201330. https:\/\/doi.org\/10.1007\/s00204-020-02711-8.","journal-title":"Arch Toxicol"},{"key":"2099_CR62","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1038\/s41420-019-0182-6","volume":"5","author":"KM McSweeney","year":"2019","unstructured":"McSweeney KM, Bozza WP, Alterovitz WL, Zhang B. Transcriptomic profiling reveals p53 as a key regulator of doxorubicin-induced cardiotoxicity. Cell Death Discov. 2019;5:102. https:\/\/doi.org\/10.1038\/s41420-019-0182-6.","journal-title":"Cell Death Discov"},{"issue":"5","key":"2099_CR63","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1038\/nm.4087","volume":"22","author":"PW Burridge","year":"2016","unstructured":"Burridge PW, Li YF, Matsa E, Wu H, Ong SG, Sharma A, et al. Human induced pluripotent stem cell-derived cardiomyocytes recapitulate the predilection of breast cancer patients to doxorubicin-induced cardiotoxicity. Nat Med. 2016;22(5):547\u201356. https:\/\/doi.org\/10.1038\/nm.4087.","journal-title":"Nat Med"},{"issue":"1","key":"2099_CR64","doi-asserted-by":"publisher","first-page":"5270","DOI":"10.1038\/s41467-021-25653-w","volume":"12","author":"M Cui","year":"2021","unstructured":"Cui M, Atmanli A, Morales MG, Tan W, Chen K, Xiao X, et al. Nrf1 promotes heart regeneration and repair by regulating proteostasis and redox balance. Nat Commun. 2021;12(1):5270. https:\/\/doi.org\/10.1038\/s41467-021-25653-w.","journal-title":"Nat Commun"},{"issue":"4","key":"2099_CR65","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1124\/mol.119.117259","volume":"96","author":"M Atwal","year":"2019","unstructured":"Atwal M, Swan RL, Rowe C, Lee KC, Lee DC, Armstrong L, et al. Intercalating TOP2 Poisons Attenuate Topoisomerase Action at Higher Concentrations. Mol Pharmacol. 2019;96(4):475\u201384. https:\/\/doi.org\/10.1124\/mol.119.117259.","journal-title":"Mol Pharmacol"},{"issue":"1","key":"2099_CR66","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1016\/j.bbrc.2019.07.029","volume":"517","author":"N Yang","year":"2019","unstructured":"Yang N, Ma H, Jiang Z, Niu L, Zhang X, Liu Y, et al. Dosing depending on SIRT3 activity attenuates doxorubicin-induced cardiotoxicity via elevated tolerance against mitochondrial dysfunction and oxidative stress. Biochem Biophys Res Commun. 2019;517(1):111\u20137. https:\/\/doi.org\/10.1016\/j.bbrc.2019.07.029.","journal-title":"Biochem Biophys Res Commun"},{"issue":"4","key":"2099_CR67","doi-asserted-by":"publisher","first-page":"e108","DOI":"10.1161\/CIRCRESAHA.119.316061","volume":"127","author":"D Han","year":"2020","unstructured":"Han D, Wang Y, Wang Y, Dai X, Zhou T, Chen J, et al. The Tumor-Suppressive Human Circular RNA CircITCH Sponges miR-330-5p to Ameliorate Doxorubicin-Induced Cardiotoxicity Through Upregulating SIRT6, Survivin, and SERCA2a. Circ Res. 2020;127(4):e108\u201325. https:\/\/doi.org\/10.1161\/CIRCRESAHA.119.316061.","journal-title":"Circ Res"},{"issue":"4","key":"2099_CR68","doi-asserted-by":"publisher","first-page":"1395","DOI":"10.1016\/j.ymthe.2020.12.035","volume":"29","author":"S Chatterjee","year":"2021","unstructured":"Chatterjee S, Hofer T, Costa A, Lu D, Batkai S, Gupta SK, et al. Telomerase therapy attenuates cardiotoxic effects of doxorubicin. Mol Ther. 2021;29(4):1395\u2013410. https:\/\/doi.org\/10.1016\/j.ymthe.2020.12.035.","journal-title":"Mol Ther"},{"issue":"1","key":"2099_CR69","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/j.jaccao.2024.01.003","volume":"6","author":"D Thomas","year":"2024","unstructured":"Thomas D, Manhas A, Sayed N. Harnessing iPSCs to Dissect Causality in Anthracycline-Induced Cardiotoxicity: All That Fits Are Not Hits. JACC CardioOncol. 2024;6(1):51\u20134. https:\/\/doi.org\/10.1016\/j.jaccao.2024.01.003.","journal-title":"JACC CardioOncol"},{"issue":"12","key":"2099_CR70","doi-asserted-by":"publisher","first-page":"2076","DOI":"10.1016\/j.stem.2021.08.006","volume":"28","author":"T Magdy","year":"2021","unstructured":"Magdy T, Jiang Z, Jouni M, Fonoudi H, Lyra-Leite D, Jung G, et al. RARG variant predictive of doxorubicin-induced cardiotoxicity identifies a cardioprotective therapy. Cell Stem Cell. 2021;28(12):2076-89 e7. https:\/\/doi.org\/10.1016\/j.stem.2021.08.006","journal-title":"Cell Stem Cell"},{"issue":"1","key":"2099_CR71","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1016\/j.jaccao.2023.11.008","volume":"6","author":"H Fonoudi","year":"2024","unstructured":"Fonoudi H, Jouni M, Cejas RB, Magdy T, Blancard M, Ge N, et al. Functional Validation of Doxorubicin-Induced Cardiotoxicity-Related Genes. JACC CardioOncol. 2024;6(1):38\u201350. https:\/\/doi.org\/10.1016\/j.jaccao.2023.11.008.","journal-title":"JACC CardioOncol"},{"issue":"1","key":"2099_CR72","doi-asserted-by":"publisher","first-page":"10363","DOI":"10.1038\/s41598-020-65979-x","volume":"10","author":"E Christidi","year":"2020","unstructured":"Christidi E, Huang H, Shafaattalab S, Maillet A, Lin E, Huang K, et al. Variation in RARG increases susceptibility to doxorubicin-induced cardiotoxicity in patient specific induced pluripotent stem cell-derived cardiomyocytes. Sci Rep. 2020;10(1):10363. https:\/\/doi.org\/10.1038\/s41598-020-65979-x.","journal-title":"Sci Rep"},{"issue":"4","key":"2099_CR73","doi-asserted-by":"publisher","first-page":"756","DOI":"10.1016\/j.stemcr.2022.03.002","volume":"17","author":"H Huang","year":"2022","unstructured":"Huang H, Christidi E, Shafaattalab S, Davis MK, Tibbits GF, Brunham LR. RARG S427L attenuates the DNA repair response to doxorubicin in induced pluripotent stem cell-derived cardiomyocytes. Stem Cell Rep. 2022;17(4):756\u201365. https:\/\/doi.org\/10.1016\/j.stemcr.2022.03.002.","journal-title":"Stem Cell Rep"},{"key":"2099_CR74","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/j.omtm.2020.10.019","volume":"20","author":"A Kondrashov","year":"2021","unstructured":"Kondrashov A, Mohd Yusof NAN, Hasan A, Goulding J, Kodagoda T, Hoang DM, et al. CRISPR\/Cas9-mediated generation and analysis of N terminus polymorphic models of beta(2)AR in isogenic hPSC-derived cardiomyocytes. Mol Ther Methods Clin Dev. 2021;20:39\u201353. https:\/\/doi.org\/10.1016\/j.omtm.2020.10.019.","journal-title":"Mol Ther Methods Clin Dev"},{"issue":"4","key":"2099_CR75","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1007\/s11886-023-01845-2","volume":"25","author":"N Sayegh","year":"2023","unstructured":"Sayegh N, Yirerong J, Agarwal N, Addison D, Fradley M, Cortes J, et al. Cardiovascular Toxicities Associated with Tyrosine Kinase Inhibitors. Curr Cardiol Rep. 2023;25(4):269\u201380. https:\/\/doi.org\/10.1007\/s11886-023-01845-2.","journal-title":"Curr Cardiol Rep"},{"issue":"6","key":"2099_CR76","doi-asserted-by":"publisher","first-page":"1697","DOI":"10.1007\/s00204-019-02448-z","volume":"93","author":"C Li","year":"2019","unstructured":"Li C, Zou R, Zhang H, Wang Y, Qiu B, Qiu S, et al. Upregulation of phosphoinositide 3-kinase prevents sunitinib-induced cardiotoxicity in vitro and in vivo. Arch Toxicol. 2019;93(6):1697\u2013712. https:\/\/doi.org\/10.1007\/s00204-019-02448-z.","journal-title":"Arch Toxicol"},{"key":"2099_CR77","doi-asserted-by":"publisher","first-page":"1229960","DOI":"10.3389\/fphar.2023.1229960","volume":"14","author":"C Altrocchi","year":"2023","unstructured":"Altrocchi C, Van Ammel K, Steemans M, Kreir M, Tekle F, Teisman A, et al. Evaluation of chronic drug-induced electrophysiological and cytotoxic effects using human-induced pluripotent stem cell-derived cardiomyocytes (hiPSC-CMs). Front Pharmacol. 2023;14:1229960. https:\/\/doi.org\/10.3389\/fphar.2023.1229960.","journal-title":"Front Pharmacol"},{"issue":"1","key":"2099_CR78","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1186\/s40360-021-00527-5","volume":"22","author":"T Matsui","year":"2021","unstructured":"Matsui T, Shinozawa T. Spontaneous recovery from sunitinib-induced disruption of sarcomere in human iPSC-cardiomyocytes and possible involvement of the Hippo pathway. BMC Pharmacol Toxicol. 2021;22(1):55. https:\/\/doi.org\/10.1186\/s40360-021-00527-5.","journal-title":"BMC Pharmacol Toxicol"},{"issue":"1","key":"2099_CR79","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1002\/ehf2.13756","volume":"9","author":"T Berecz","year":"2022","unstructured":"Berecz T, Yiu A, Vittay O, Orsolits B, Mioulane M, Dos Remedios CG, et al. Transcriptional co-activators YAP1-TAZ of Hippo signalling in doxorubicin-induced cardiomyopathy. ESC Heart Fail. 2022;9(1):224\u201335. https:\/\/doi.org\/10.1002\/ehf2.13756.","journal-title":"ESC Heart Fail"},{"issue":"1","key":"2099_CR80","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1186\/s12916-023-02838-2","volume":"21","author":"H Wang","year":"2023","unstructured":"Wang H, Wang Y, Li J, He Z, Boswell SA, Chung M, et al. Three tyrosine kinase inhibitors cause cardiotoxicity by inducing endoplasmic reticulum stress and inflammation in cardiomyocytes. BMC Med. 2023;21(1):147. https:\/\/doi.org\/10.1186\/s12916-023-02838-2.","journal-title":"BMC Med"},{"issue":"5","key":"2099_CR81","doi-asserted-by":"publisher","first-page":"482","DOI":"10.1161\/CIRCRESAHA.123.323683","volume":"134","author":"G Yan","year":"2024","unstructured":"Yan G, Han Z, Kwon Y, Jousma J, Nukala SB, Prosser BL, et al. Integrated Stress Response Potentiates Ponatinib-Induced Cardiotoxicity. Circ Res. 2024;134(5):482\u2013501. https:\/\/doi.org\/10.1161\/CIRCRESAHA.123.323683.","journal-title":"Circ Res"},{"issue":"1","key":"2099_CR82","doi-asserted-by":"publisher","first-page":"7123","DOI":"10.1038\/s41598-024-57686-8","volume":"14","author":"EA Pinheiro","year":"2024","unstructured":"Pinheiro EA, DeKeyser JM, Lenny B, Sapkota Y, Burridge PW. Nilotinib-induced alterations in endothelial cell function recapitulate clinical vascular phenotypes independent of ABL1. Sci Rep. 2024;14(1):7123. https:\/\/doi.org\/10.1038\/s41598-024-57686-8.","journal-title":"Sci Rep"},{"issue":"2","key":"2099_CR83","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1056\/NEJMoa1411321","volume":"372","author":"AK Stewart","year":"2015","unstructured":"Stewart AK, Rajkumar SV, Dimopoulos MA, Masszi T, Spicka I, Oriol A, et al. Carfilzomib, lenalidomide, and dexamethasone for relapsed multiple myeloma. N Engl J Med. 2015;372(2):142\u201352. https:\/\/doi.org\/10.1056\/NEJMoa1411321.","journal-title":"N Engl J Med"}],"container-title":["Current Cardiology Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11886-024-02099-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11886-024-02099-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11886-024-02099-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,6]],"date-time":"2024-09-06T11:54:06Z","timestamp":1725623646000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11886-024-02099-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,23]]},"references-count":83,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2024,9]]}},"alternative-id":["2099"],"URL":"https:\/\/doi.org\/10.1007\/s11886-024-02099-2","relation":{},"ISSN":["1523-3782","1534-3170"],"issn-type":[{"value":"1523-3782","type":"print"},{"value":"1534-3170","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,7,23]]},"assertion":[{"value":"9 July 2024","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 July 2024","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This article does not contain any studies with human or animal subjects performed by any of the authors.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human and Animal Rights and Informed Consent"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}}]}}